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1 2S(OH)zD has numerous actions on many tissues . Analogs 
of 1,25(OH)2D are being sought that are selective, to further 
an understanding of the mechanisms of action of 
1,25(OHhD and to improve its therapeutic efficacy. Toward 
these ends we examined eight analogs of 1,25(OH)zD for 
their ability to regulate 250HD metabolism by keratino-
cytes. Ch.oosin~ th~ .three I~ost potent, .we tl:en ex~mined 
their abihty to lI1hlbit keratlI10cyte prolIferatIOn, stimulate 
cornified envelope formation (a marker of differentiation), 
and bind to the 1,25(OH)zD receptor (VDR). 1,25(OHh-
24F2-D, 1,25(OH}2-616-D, and 1,25(OH)z-616,23yne-D 
proved the most potent in inhibiting 1,25(OH}2D produc-
tion and stimulating 24,25(OHhD production, being ap-
proximately 10-100 times more potent than 1,25(OHhD 
itself. 1,25(OH}2-616-D had the highest affinity for the 
T he most important physiologic role for l ,2S(OHhD is in controlling calcium and phosphate homeostasis, acting principally on bone, gut, and kidney. How-ever, in the past decade it has become widely appre-ciated that l,2S(OH)zD has receptors in and alters the 
function of a wide range of cells including the skin (recently re-
viewed in [1,2] . Keratinocytes are of particular interest as they not 
only respond to e~o~enous l ,2S(OH)2D with changes in prolifera-
tion and differentiation [3 - 7]. but produce l,25(OHhD [8,9], sug-
gesting that l,2S(OH)zD may play an autocrine or paracrine role in 
the skin. 
The ability of l ,2S(OHhD to regulate the proliferation and dif-
ferentiation of a number of cell types has generated interest not only 
in understanding the mechanisms by which these actions are me-
diated but in exploiting such actions therapeuti~al.ly . In skin most 
attention has been paid to the treatment of psonasls With tillS hor-
mone [10,11] . However, because of the potential toxicity in using 
l,25(OHhD itself due to hypercalcemia, analogs of l ,2S(OH)2D 
are being produced and studied l1l an effort to obtam compounds 
[hat retain some of the effects of l,2S(OH)2D (e.g., its ability to 
inhibit pwliferation and stimulate differentiation) but nor others 
(e.g., its ability to stimulate intestinal calcium transport and bone 
resorption). Several analogs have been developed that appear to be 
selective in their actIOns and that are currently bemg tested for use 111 
psoriasis [12,13]. None of these analogs has been evaluated for its 
influence on l ,2S(OH)2D production by the skin . 
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VDR (fourfold higher than that for 1,25 (OH)zD itself) and 
had the greatest ability both to inhibit proliferation and to 
stimulate differentiation. 1,25(OH}2-616,23yne-D also had a 
higher affinity for the VDR but was of less or equal potency 
in st.imul~ting cornified envelope formation and inhibiting 
prolIferatIOn. l,25(OH)z-24F2-D, which was the most po-
tent regulator of 250HD metabolism, had a lower affinity 
for the VDR and was less potent than l,25 (OH)zD in inhib-
iting proliferation. Our results indicate that even in the same 
cell different anal?gs have different rank orders of potency 
for the vanous actIOns of l,25(OH)zD. Key words: calcitriol 
/vitamin D analogs/keratinocytes/cornified envelope/pro-
liferation/vitamin D receptor. ] Il7vest Dermato/ 101 :713-
718,1993 
In this report we evaluated eight analogs first for th eir ability to 
regulate l,25(OHhD and 24,2S(OH)2D production by keratino-
cytes and then, choosmg the most potent, for their binding to the 
1,2S(OHhD receptor (VDR) and for th eir abi li ty to regulate prolif-
eration and differentiation. Our studies suggest that certain alter-
ations in the l,2S(OH)2D molecule increase its potency either by 
increasing its affinity for the VDR or by increasing its resistance to 
catabolism. 
MATERIALS AND METHODS 
Materials The following analogs were obtained as gifts from Dr. Milan 
Uskokovic (Hoffmann-LaRoche, Nutley, NJ): 1,25-dihyd roxy-26,27-hex-
adeuterocholecalcifero l (1,25(OH),-26,27D6D); 1,25-dihydroxy-24-di-
fluorocholecalciferol (1 ,25(OH)2-24F2-D); 1,25-dihydroxy-.0,22-choleca l-
ci ferol (l ,25(OH),-.0,22-D); 1,25-dihydroxyergocalciferol (1,25(OH)2D2); 
1,25R,26-trihydroxy-.0,22-cholecalcifero l (1,25,26(OH),_.0,22D); 1,25-di-
hydroxy-23-yne-cholecalCIferol (1,25(OH),-23yne-D); 1,25-dihydroxy-
.0,22-cholecalclferol (l ,25(OH),-6.22-D); and l ,25-dihydroxy-.0,22,23yne-
choleca lciferol (1 ,25(OH),-.0, 16,23yne_D) . The structures of these 
compounds are found in Fig 1. These compounds were solubilized in eth-
anol and their concentrations determined [rom their ultraviolet (UV) spectra 
using an extinction coeffi cient at 00264 of 18,500. For use in the experi-
ments , the compounds were made up in 10% bovine serum albumin, which 
was added to the cultures in 100X the final concentration. 
Cell Culture Second-passage keratinocytcs isolated from neonatal 
human foreskins were used in these studies . They were grown in serum-free 
keratinocyte growth medium (KGM) obtained from C lonetics Corporation 
(San Diego, CAl as described previously [1 4J. Keratinocytcs were assayed at 
or just prior to reaching confluence. 
2S0HD Metabolism Production of 1,25(O H), D and 24,25(OH)2D 
fr0111 250HD by keratinocytes was eva luated as described previous ly [9J. In 
brief, the various concentra tions of the analogs o r 1 ,25(OH)'D were added 
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Figure 1. Structure of l,25(OHhD (A) and the eight analogs (B) used in 
this study. 
to the cultures 16 h prior to assay. Following the overnight incubation with 
the analogs, the cells were washed with fresh medium without the analogs, 
then 0.1 uCi 25-hydroxy [26,27methyl-'H] vitamin D,(148-180 Cij 
mmol) (Amersham Corp, Arlington Hts, IL) was added in 10 ul ethanol to 
the 1 ml fresh medium covering the cells. After 1 h incubation at 37"C, the 
cells and medium were extracted into chloroform:methanol, and the chloro-
form-soluble material chromatographed on HPLC using a 97:3 - 90: 1 0 gra-
dient of hexane:isopropanol and a Zorbax-Sil column (DuPont, Wilming-
ton, DE). The radioactive peaks were detected and quantitated with a 
Radiomatics Flo One-HP detector. 
Cornified Envelope Synthesis This assay was performed as previously 
described [6). In brief, 2 uCi/ml '5S-methionine was added to the cultures 
48 h before harvest. Two hours before harvest the cells were exposed to 10- 6 
M ionomycin to maximize cornified envelope formation. The cells were 
then washed 3 X in phosphate-buffered saline, and the total radioactivity 
incorporated into TCA precipitable material (total protein synthesis) as well 
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as that incorporated into sodium dodecylsulfate/d ithioth reitol-insoluble 
material (cornified envelopes) were determined. 
Cellular Proliferation 'H-thymidine incorporation was determined as 
previously described [15) . In brief, the cel ls were incubated with 2 uCijml 
' H-thymidine for 2 h before determining the amount of radioactivi ty incor-
porated into TCA-precipitable material. 
Receptor Binding The cytosol receptor assay for l ,25(OHhD binding 
was performed as previously described [1 6]. The keratinocytes were ex-
tracted in buffer containing 50 mM Tris-HCI, 300 mM KC1, 1.5 mM ethyl-
enediamine tetraacetic acid (EDT A) , 5 mM dithiothreitol , and 10 mM so-
dium molybdate, pH 7.4 (TKEDM), and the 100,000 X g supernatant used 
as the source of the receptor. Three hundred eighty microliters cytosol 
(200 ug protein) was incubated for 8 h on ice with 10,000 cpm 
' H-1,25(OHhD plus up to 3 nM analog or 1,25(OHhD added in 20 ul 
ethanol. Unbound radioactivity was removed by charcoal extraction, and the 
radioactivity remaining in the supernatant determined. This range for each 
analog tested showed saturation of binding at the highest concentrations. 
Non-specific binding was subtracted from the results in performing the 
Scatchard analysis. 
Statistical Analysis The data were analyzed by multivariable analysis of 
variance, linear regression, and least-significant difference pairwise compar-
isons to establish different potencies of the analogs in the various assays. 
These analyses were performed by the program Statstix (Analytic Software, 
St. Paul, MN) 
RESULTS 
The ability of the various analogs to inhibit l,25(OH}zD produc-
tion and induce 24,25(OHhD production is shown in Fig 2A, and 
B, respectively. The control cultures (receiving vehicle only) pro-
duced 320 ± 15 fmo l/mg l,25(OH)2D (8.1% conversion) and no 
24,25(OHhD in this experiment. The rank order of potency for 
inhibiting l,25(OH}zD production was l,25(OHh-24F2-D > 
1,25 (OHh- t,16_D > 1,25 (OHh- t,16,23yne_D > 1,25 (OH)z-
23yne-D> 1,25 (OHh-26,27D6-D > 1,25 (OHh- t,22_D > 
1,2S(OH)zD2 = l,25,26(OHh-t,22-D. A similar rank order of 
potency was observed for the induction of 24,25(OHhD produc-
tion : 1,25 (OH)z-24F2-D > 1,25 (OHh- t, 16_D > 1,25 (OHh -
t,16,23yne-D> 1,25 (OH)z-23yne-D > 1,25 (OH)z-26 ,27D6-
D> l,25(OH}zD2 > l,25 ,26-(OHh-t,22-D = l,25(OHh-t,22-D. 
Estimation of the half maximally effective doses required are found 
in Table l. 
Regulation of 250HD metabolism by 1,25(OHhD and its ana-
logs is a sensitive marker of the influence of these agents on the 
keratinocyte. In this experiment 10- 12 M 1,25(OH)z-24F2-D, 
1,25 (OH)z-t,1 6_D, or 1,25(OH)2-t,16,23yne-D was sufficient 
to markedly inhibit 1,25(0 HhD production and stimulare 
24,25(OHhD production. By 10- to M these analogs plus 
l,25(OH)z-23yne-D and l ,25 (OH}z-26,27D6-D had completely 
suppressed l,25(OH)zD production and maximally stimulated 
24,25(OH)zD production. Based on previous results with 
l,25(OH)2D J [6 ,9,17] and the current results with 1,25(OHhD2, 
the three most potent analogs 1,25(OHh-24F2-D, 1,25(OH)z_t,16-
0 , and 1,25(OH)z-t,16,23yne-D, were one to two orders of magni-
tude more potent than l,25(OH)2D. 
In interpreting the ability of the different analogs to stimulate 
24,25(OH)zD production, one must consider that these compounds 
induce not only the 24-hydroxylase but a whole spectrum of cata-
bolic enzymes that metabolize not only 250HD and 1,25(OH)2D, 
but 24,25(OHhD as well [9]. Although the I-h incubation period 
used in this assay was chosen to minimize this effect, the results in 
Fig 2B indicate that catabolism of24,25(OH)2D contributed to the 
results obtained. Thus, whereas the more potent analogs stimulated 
24,25(OH)2D production at 10- 12 M, higher concentrations of 
these analogs led to a reduced level of recoverable 24,2S(OH):zD 
after 1 h incubation. Furthermore, these induced catabolic enzymes 
can metabolize the analogs themselves, potentially resulting in an 
underestimation of the potency of an analog for regulating the 10:-
and 24-hydroxylase. This appears to be more of a concern for esti-
mating the EDso for the 24-hydroxylase than the la-hydroxylase; 
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Figure 2 . Effect of ei~ht ana logs of 1,25(OH),O, to inhibit 1.25(OH),0 
production (A) and stimulate 24,25(OH),0 production (B). The data dc-
pict the percent of substrate (250HO) converted to 1.25(OH),0 (A) or 
24 25(OHhD (B) after 1 h incubation. The kcratinocytes were incubated 
wi;h the various analogs at the indicated concentrations for 16 h before this 
assay was performed. The data points represent the mean of duplicate deter-
minations that 111 all cases were wlth1l1 8% of the mean. 26,27 06 = 
1 25(OHh-26.27060. 24F2 = 1.25(OH),-24F2-O, 22ene = 1.25(OHh-
A22_D. l,2S,26enc = 1,25,26(OH)3-1I22-O,23yne = 1,25(OH),-23ync-0, 
16ene,23yne = 1.25(OHh-1I16,23ync-0. 16cne = 1,25(OHh-1I16-0. 
inh ibition of the la-hydroxylase occurs more rapidly than induc-
tion of the 24-hydroxylase, and its activity is disappearing as poten-
tial catabolism of its product is induced [9]. 
The l,25(OHlz-24F2-D analog might be expected to be more 
potent than l,25(OHhD because of the stability of the fluoride-car-
bon bond in position C-24. limiting hydroxylation at this important 
site of l,25(OHlzD catabolism. Likewise, the 23yne bond would 
prevent hydroxylation at either C23 or C24. However, the mecha-
nism by which the double bond at C16 conferred potency is less 
dear. To assess whether at least part of the mechanism involved a 
greater affinity for the 1,25(OHlzD receptor, we evaluated the 
binding of l,25(OH)2-24F2-D, 1 ,25(OHh-[,.16_D, and 1.25(OHh-
6 26,23yne-D to the VDR in keratinocytes. These results are shown 
in Fig 3 . The binding data depicted in A are replotted using Scat-
chard analysis in B. As can be seen, the double bond at C-16 con-
ferred on 1,25(OH)z-1I16_D a fourfo ld greater affinity (Kd = 
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Table I. Effect of Various Calcitriol Analogs on 
250HD Metabolism" 
1,25-26,27 0 6-03 
1,25-24F2-O, 
1,25-L122-0, 
1,25 O2 
1,25.26-L122-0, 
1,25-23ync-O, 
1.25-6 '623ync-0) 
1,25-6 '6-0, 
1 Hydroxylase 
10- 11 c.d 
< 10 - 12, 
2 X 10- 11 d,c 
5XIO- ll c 
5XIO- llc 
3 X 10 - 12b.c.d 
10 - 120•10.< 
< 10 - 12 , ... 
EDso(M) 
24 Hydroxylase 
10 - 11 ... c 
10 - 12 < 
2Xl0- lI e 
10 - lOe 
2 X 1O - IOe 
8 X 10- 12 , 
6 X 10 - 12>.10 
2 X 10- 12 , 
'Comparison of eight calcitriol analogs regarding their abiliry to inhibit 
I ,25(OH),D production and stimulate 24,25(OH),D production. The EDso was esti-
mated ~rom the data shown in Fig 1. The ability of these analogs to stimulate their own 
catabohsm as well as that of the naturally produced vitamin D metabolites results in an 
overes.'imation of the ED,. especially for stimulation of the 24-hydroxylase. The su-
perscnpts tndlc~tC. analogs whose effects on the 1- or 24-hydroxylasc activities afC 
comparable statIStically. Ana logs with the same superscript cannot be distinguished 
s t.a~lstIcally ~lt l~ regard to their effects on the hydroxylascs using least significant 
difference pauwlse comparisons. 
100pM) for the VDR than 1,25(OH)2D (Kd = 462pM) itself. Ad-
ditIOn of the 23yne bond in 1,25(OH)'-[,.16,23yne-D weakened this 
affi11lty (Kd = 257pM), but this compound still had a 
higher affinity than l,25(OH)2D. The difluoro substitutions in 
1,25(OH)2-24F2-D also reduced the affinity (Kd = 661pM) of the 
analog for the VDR. 
When evaluated for their antiproliferative activities (Fig 4) 
1,25(OH)2-[,. '6-D proved to be the most potent of the analog~ 
tested. 1,25(OH),-[,.'6,23yue-D was equivalent to l,25(OH),D in 
its antiproliferative effects, whereas 1,25(OH)2-24F2-D was less 
potent .. However, none of the analogs were potent antiproliferative 
agents 111 tl1lS assay. Only 1.25(OH)2-[,.16-D showed inhibition of 
3H-thymidine incorporation at 10- 8 M, and even at 10- 6 M, the 
inhibition by 1,25(OH)2D and 1,25(OH)2-[,.16,23yne-D was less 
than 50%. 
When eva luated for their prodifferentiating effects as assessed by 
stimulation of cornified envelope formation (Fig 5), 1,25(OH)z-
[,.16_D aga1l1 proved to be the most potent ana log, with stimulation 
seen even at 10- 1) M. 1,25(OH)2-24F2-D was equivalent to 
1,25(OH),D, whereas l ,25(OH)'-[,.16,23yne-D was less potent 
than 1,25(OHhD. Unlike the antiproliferative assay described 
above, cornified envelope formation responded to much lower 
doses of 1,25(OH)2D and its analogs; in this experiment only 
1 ,25(OH)z-[,.16,23yne-D fai led to stimulate cornified envelope for-
mation at 10- 11 M. 
DISCUSSION 
The observation that VDRs exist in a wide variety of cells that 
respond to 1,25(OHhD in a wide variety of ways [1] has marked ly 
increased interest in the therapeutic potential of this molecule [18] . 
Efforts to develop analogs that selectively exert some but not all of 
these ac tions have accelerated over the past several years. In evaluat-
ing the potency of these analogs ill villo and ill I, itro, at least five 
factors need to be considered: 1) affinity of the molecule for the 
VDR. 2) affinity of the molecule for vitamin 0 binding protein 
(DBP) in the media or blood, 3) non-genomic actions that may not 
be mediated by the classic VDR, 4) rate of uptake by the target cell, 
and 5) rate of catabolism within the target cel l or clearance from th e 
body. 
Three analogs that have received considerable attention in the 
past several years, calcipotriol (MC903), 22 oxa calcitriol (OCT), 
and 1,25(OHh-[,.'6,23yne-D bind to the VDR with equa l or 
slightly lower affinity than 1,25(OH)2D [1 9- 23]. Their greater 
potency ill lIit ro and their relative lack of abi lity to raise serum 
calcium or stimulate intestinal calcium transport i'l lIillO may be 
attributed in part to their much reduced affinity for DBP 
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Figure 3. Affinity of various analogs for the keratinocyte VDR. The 
displacement of lH-l,25(OH)'D from the VDR by various analogs of 
1.25(OH),D is shown in A. Scarchard analysis of the binding data is shown 
in B. The identification of the analogs is given in the legend to Fig 2. By 
least significant difference pairwise comparisons all four analogs were 
found to be significantly different from each other in their binding to the 
VDR. The a.ffinities ± SE (and correlation coefficient for the regression 
obtained in the analysis) of the different analogs calculated from Scarchard 
analysis were 1,25(OH),D; 462 ± 52 pM (r = 0.91 1); 1,25(OH),-
~'6.23yne-D.257 ± 34 pM (f = 0.885); 1.25(OH)2-24F2-D,661 ± 
64 pM (r = 0.933); 1.25(OHh-'i716D. I00 ± 17 pM (r = 0.855). The 
greater affinity of 1.25(OHh-~ 1 6_D and 1.25(OHh-~16.23yne-D for the 
VDR compared to 1.25(OH),Dl itself is apparent. 
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Figure 4. Inhibition of kcratinocyte proliferation by various analogs of 
1.25(OHhD. 'H-thymidine incorporation into TeA-precipitable material 
was measured following a 2-d incubation with the indicated concentrations 
of the analogs or 1.25(OH),O,. The data points show the mean ± so of 
triplicate determinations. By least significant difference pairwise compari-
sons. 1.25(OH),-616-O was significantly more potent and 1,25(OH),-
24F2-D significantly less potent thall the other analogs and 1.2S(OH),O 
itSelf. 
[19,20 ,24,25]. Thus, in serum containing media analogs with a 
lower affinity for DBP have a higher free concentration for any 
given total ~oncentration when compared to 1,25(OH)2D [19], 
whereas in VIVO these compounds are more rapIdly cleared [25]. Such 
properties would increase their relative po~encies ill vitro but reduce 
[hem in vivo. These structure functIon studIes suggest that modifica-
tions that reduce the flexibility of the side chain (introduction of 
double or triple bonds) reduce binding to DBP more than to the 
VDR. 
The extent to which non-VDR-mediated actions playa role in 
[he selective response to the different analogs has received less at-
tention. However. Faruch-Carson et al [26] have identified several 
analogs that stimulate calcium uptake by osteosarcoma cells but 
have little affinity for the VDR, whereas 1,25(OHh-6 16,23yne-D, 
which binds well to the VDR, is considerably less effective than 
I 25(OHhD in stimulating calcium uptake by these cells. At this 
~int, structural changes that would predictably enhance the ability 
of an analog to stimulate calcium uptake without binding to the 
VDR are not clear. 
Rate of catabolism of the analog within the cell also contributes to 
itS relative potency. The stability of the carbon-fluoride bond has 
been exploited by various investigators to evaluate the role of differ-
ent hydroxylation steps in the bioactivation and catabolism of vita-
min D metabolites [27 -30]. From such studies 1,25(OHh-24F2-D 
emerged as the first analog of 1 ,25(0 H)2D found to be more potent 
than 1,25(OhD if, vivo [28]. Substitution of fluoride for hydrogen in 
me C24 postion appears to have little impact on its affinity for the 
VDR [31], although as reported here it causes a subtle reduction. 
Because 250HD and 1,25(OHhD undergo catabolism through a 
, pathway beginning with 24-hydroxylation [32], inhibition of this 
hydroxylation step would be expected to reduce catabolism. We 
[33] have show~l ~his to be true by substituting tritium for hydro?en 
in the C24 pOSitIOn, and the same would be expected for substitu-
tions w ith fluoride or with elimination of the hydrogens, as by 
inserting a triple bond between C23-C24 (23 yne) . Substitution of 
fluoride groups for the hydrogens in C26,27 also increases the po-
tency of the analog despite reducing its affinity for the VDR 
[29,30]; this substitution would also be expected to reduce catabo-
lism [33] through the pathway involving 26 or 27 hydroxylation. 
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The analogs tested for their ability to regulate 250HD metabo-
lism by keratinocytes in this report contained modifications that 
would be expected to alter both their affinity for the VDR and DBP 
and their rate of catabolism. In these experiments, the media con-
tained no serum, so differences in binding to DBP is not a consider-
ation. However, the keratinocytes were incubated with the analogs 
for 16 h before being assayed for 250HD metabolism and for 
longer periods before being assayed for proliferation and cornified 
env.elope .formation. Extensive catabolism of 1,25(OHhD occurs 
durmg thiS amount of time [9]. Variations in rates of metabolism of 
the analogs cc:>uld alter their relative potencies, and this could vaty 
among the dIfferent assays employed. In this regard the analogs 
expected to reSISt 24- or 26-hydroxylation, 1,25(OH)2-24F2-D , 
1,25(OHh-23yne-D, 1,25(OHh-6 16,23yne-D. and 1,25(OHh-
26,27D6-D were all more potent than 1,25(OH)2D2 in regulating 
250HD metabolism. 
The poten~y of 1,25(OHh-L>t6_D, however, is not readily ex-
plamed by resIstance to catabolism. Therefore, we assessed its affin-
ity for the VDR and found it to have a fourfold higher affinity than 
1,25(OH)!!D . To our knowledge this is the first analog to show 
greater affilllty for the VDR than 1.25(OHhD itself. Addition of 
the 23yne bond reduced this affinity, as did substitution of fluoride 
for hydrogen in the 24 position, strengthening our conclusion that 
these latter changes add potency primarily by increasing stability. 
The increas~d affinity of 1,25(OH)2-616_D for the VDR may 
also. have contnb~ted to its greater potency in inhibiting the prolif-
eratIon of keratmocytes and stimulating their ability to form 
cornified envelopes. 1,25(OHh-24F2-D was less potent than 
1 ,25.(O~)2D in inhibitin.g keratinocyte proliferation, possibly re-
f1ectmg ItS reduced affilllty for the VDR, but was equivalent to 
1,25(OHhD in stimulating cornified envelope formation. 
1 ,25(OH)2-L> 16,23yne_D had the reverse profile. being a less potent 
stimulator of corlllfied envelope formation than inhibitor of prolif-
eration. These data suggest that affinity for the VDR may be of 
greater importance for predicting effects on proliferation tha.n on 
cornified envelope formation. 
In a recent publication Chen et al [34] evaluated a Ilumber of 
analogs. including several examined in our study. for their effects on 
a variety of actions including keratinocyte proliferation, cornified 
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Figure 5. Stimulation of cornified cnvelope formation by various analogs 
of 1.2S(OH),O. 3SS-mcthioninc incorporation into 50S-0TT-insolublc 
material is measured after incubation of the keratinocytc with the indicated 
conccntrations of the analogs or 1.2S(OH),O,. The data show mean ± SO 
of triplicate determinations for the analogs and mean ± range of duplicate 
dcterminations for 1,25(OH)20 ,. By Icast significant differcnce pairwisc 
comparisons, 1,2S(OHh-l;\6-0 was significantly more potcnt and 
1 ,2S(OH),-6 16,23yne-O significantly Icss potent than the other analogs. 
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envelope formation, and binding to the rat intestinal VDR. Their 
results differed from ours in that both l,25(OHh-L'>.16-D and 
l,25(OH)z-24F2-D had a higher affinity for the VDR, and that 
l,25(OHh-L'>.16-D was less potent in its antiproliferattve actIOns and 
no more potent in its ability to stimulate corJ1Ined envelopes than 
l,25(OHhD despite its greater affinity for the VDR, where~s 
l,25{OH)2-L'>.16,23yne-D was more potent than l,25{OH)2D 111 
these actions despite a reduced affinity for the VDR. The explana-
tion for these differences is not readily apparent but could involve 
species differences with respect to receptor binding, and different 
culture and assay conditions with respect to the proliferation and 
differentiation assays. 
In summary, we have evaluated eight an~logs of l,25{OHhD for 
their ability to regulate 250HD metabolism by the keratll1ocyte. 
The three most potent analogs were further studie~ for their affinity 
to the VDR and their abi lity to regulate prohferatlOn and corJ1Ified 
envelope formation. Insertion of a double bond in the C ring mark-
ed ly increases the affinity of the analog for the VDR an? enhances 
its potency in all actions ofl,25{OHhD examl11ed. AlterIng t~e Side 
chain in a manner expected to reduce cataboltsm reduced affimty for 
the VDR and had disparate effects on potency depending on the 
assay employed. Selectivity of analogs can be conf~rred with l11?di-
fications that exert disparate effects on analog stablhty, their abIlity 
to bind to DBP and VDR, and, possibly, their actions within the 
cell. 
We appreciate tile editorial and adlllin istratilic assistance oj Vicky Lee atld Ken 
Yoder. 
This lVork was sllpported by grant AR38386 frO Ill the National I/IS/ illltcs oj 
Hea ltft . 
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